close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

54.37 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond
These companies are jockeying for position in a potential $150 billion market opportunity. 
Via The Motley Fool
'No Place Is Risk-Free Until The World Is Polio-Free:' Bill Gates Urges Global Action To Close Deadly Immunity Gaps
Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps. 
Via Benzinga
Benzinga Bulls And Bears: Stellantis, Papa John's, Oklo — And Trade Tensions Shake Chip Stocks
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Topics World Trade
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder
Via Stocktwits
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet
Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure. 
Via Benzinga
Topics ETFs Government
Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032
Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but... 
Via Benzinga
Topics Government Intellectual Property
Novo Nordisk Stock Is Falling Friday: What's Driving The Action?
Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that began Thursday. 
Via Benzinga
Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.
Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs. 
Via Investor's Business Daily
Topics Government
Novo Nordisk Hires US Pharma Veteran After Trump Touts ‘Much Lower’ Prices Of Ozempic
Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs. 
Via Stocktwits
Topics Government
Eli Lilly Shares Are Trading Lower Friday: What's Going On?
Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price. 
Via Benzinga
Topics Government
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer. 
Via Benzinga
Topics Government
Market Jitters: Dow Dips Amid Bank Fears While Eli Lilly and Novo Nordisk Tumble on Trump's Drug Pricing Comments
The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently,... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Regional Banks’ Credit Concerns Drag Dow Futures: NVO, WAL, ZION, IBKR Among Stocks To Watch
While Dow Jones futures were down by 0.13% at the time of writing, the S&P 500 futures declined 0.41%. 
Via Stocktwits
Topics ETFs Earnings Fraud
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?
These stocks have climbed in the triple digits over the past few years. 
Via The Motley Fool
Eli Lilly, Novo Nordisk Stocks Fall After-Hours As Trump Pledges Swift Price Cuts For ‘Fat-Loss Drugs’
Novo Nordisk is also continuing discussions with the administration under the Most Favored Nation policy aimed at linking U.S. drug costs to global benchmarks. 
Via Stocktwits
Topics Economy Government
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price. 
Via Benzinga
Topics Government
What's Driving the Market Sentiment Around Novo Nordisk AS?
 
Via Benzinga
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem
Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on healthcare. 
Via Benzinga
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Find out if the deal Omeros announced is enough of a reason to buy this stock. 
Via The Motley Fool
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside
The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart. 
Via Stocktwits
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments 
Via MarketBeat
Topics World Trade
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties. 
Via Benzinga
Meet the 1.4% Yield Dividend Stock That Could Soar in 2026
The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value. 
Via The Motley Fool
Why Is Scholar Rock Stock Trading Lower On Monday?
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial. 
Via Benzinga
Why Are Regeneron And Scholar Rock Shares Falling On Monday?
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
The Smartest Growth Stock to Buy With $100 Right Now
This beaten-down drugmaker is well positioned to turn things around. 
Via The Motley Fool
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
Now may be the time to invest in drug companies, as they just slipped the tariff noose. 
Via The Motley Fool
Topics ETFs Government World Trade
3 Top Healthcare Stocks to Buy in October
Healthcare stocks haven't been very popular this year. It could be a great time to buy some of the industry's leaders. 
Via The Motley Fool
Topics Economy Government Intellectual Property
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Example of Affordable Growth
Novo Nordisk exemplifies affordable growth, combining strong revenue and earnings expansion with a reasonable valuation and top-tier profitability. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today